Phil Walls Interviewed by Risk & Insurance on the Future of Drugs in Workers’ Comp

Posted on by myMatrixx

Recently, myMatrixx Chief Clinical Officer, Phil Walls, sat down with Risk & Insurance Magazine for an interview where he discusses a range of topics surrounding the high cost of drugs in the current marketplace. The conversation takes place ahead of his presentation at the 2019 National Workers’ Compensation and Disability Conference® & Expo. Walls believes this is an important topic because while dramatic increases in drug prices make headlines and are the subject of congressional hearings, it is ultimately up to the industry, including workers’ comp PBMs, to make changes.

Among other price drivers, Walls pinpoints unnecessary prescriptions, specialty drugs and so-called “private label” formulations from physicians. To help manage rising costs, Walls shares some of the effective strategies that stakeholders can turn to, including working with a clinically driven PBM. You can read the full interview at the Risk & Insurance website here.